Datasets:

---

Recag

/

Rp_CommonC_275

like 0

ERROR: type should be string, got "https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2OTgwNC10cmVhdG1lbnQ=\nDrugs & Diseases > Dermatology\nAcne Vulgaris Treatment & Management\nAuthor: Jaggi Rao, MD, FRCPC; Chief Editor: William D James, MD more...\nSections Acne Vulgaris\nRetinoid-like Agents\nEstrogens/Progestins\nAldosterone Antagonists, Selective\nTreatment should be directed toward the known pathogenic factors involved in acne. These include follicular hyperproliferation, excess sebum, Cutibacterium acnes (formerly Propionibacterium acnes) infection, and inflammation. The grade and severity of the acne help in determining which of the following treatments, alone or in combination, is most appropriate.\nCurrent consensus recommends a combination of topical retinoid and antimicrobial therapy as first-line therapy for almost all patients with acne. [2] The superior efficacy of this combination, compared with either monotherapy, results from complementary mechanisms of action targeting different pathogenic factors. Retinoids reduce abnormal desquamation, are comedolytic, and have some anti-inflammatory effects, whereas benzoyl peroxide is antimicrobial with some keratolytic effects and antibiotics have anti-inflammatory and antimicrobial effects. [2]\nNote the images below.\nAcne with reactive hyperpigmentation; before treatment.\nAcne with reactive hyperpigmentation; after treatment.\nTopical retinoids are comedolytic and anti-inflammatory. They normalize follicular hyperproliferation and hyperkeratinization. Topical retinoids reduce the numbers of microcomedones, comedones, and inflammatory lesions. [35] Topical retinoids should be initiated as first-line therapy for both comedonal and inflammatory acne lesions and continued as maintenance therapy to inhibit further microcomedone formation. [35]\nThe most commonly prescribed topical retinoids for acne vulgaris include adapalene, tazarotene, and tretinoin. These retinoids should be applied once daily to clean, dry skin, but they may need to be applied less frequently if irritation occurs. Skin irritation with peeling and redness may be associated with the early use of topical retinoids and typically resolves within the first few weeks of use. [36] The use of mild, nonirritating cleansers and noncomedogenic moisturizers may help reduce this irritation. [35] Alternate-day dosing may be used if irritation persists.\nTopical retinoids thin the stratum corneum, and they have been associated with sun sensitivity. [37] Instruct patients about sun protection. Also see Sunscreens and Photoprotection.\nTopical antibiotics are mainly used for their role against C acnes (formerly P acnes). They may also have anti-inflammatory properties. Topical antibiotics are not comedolytic, and bacterial resistance may develop to any of these agents. Commonly prescribed topical antibiotics for acne vulgaris include clindamycin, erythromycin, and, more recently, dapsone and minocycline.\nTopical dapsone is a new sulfone antibiotic with anti-inflammatory properties that has been shown to be effective for mild-to-moderate acne, and it has a convenient once-daily application schedule. [38] It is available as 5% twice-daily and 7.5% once-daily formulations. [38] The current American Academy of Dermatology guidelines preceded the FDA approval of the 7.5% formulation. Although no research has compared the efficacy of the 5% formulation with the 7.5% formulation, both have been separately shown to be efficacious and safe. The 7.5% formulation has the additional compliance factor of once-daily application. [33, 38]\nMinocycline topical foam 4% was evaluated in three 12-week phase 3 trials (n=2418) in patients aged 9 years or older. Each study demonstrated statistically significant disease improvement with minocycline topical compared with vehicle for the coprimary endpoint of absolute reduction of inflammatory lesions and investigator assessment. [39, 40]\nAntibiotic resistance in C acnes (formerly P acnes) is common and is a significant threat to acne treatment. [33] Antimicrobials should be combined with a topical retinoids for greater clearing of lesions and to increase the potential for shortened antibiotic treatment. They should be used with benzoyl peroxide to reduce the likelihood of resistance. [2] Concurrent use of oral and topical antibiotics should be avoided and should not be used as monotherapy. If acne relapses, use the same antibiotic if it was previously effective. It may also be helpful to use benzoyl peroxide for 5-7 days between antibiotic courses to reduce resistance in organisms on the skin. [2]\nBenzoyl peroxide products are also effective against C acnes (formerly P acnes), and bacterial resistance to benzoyl peroxide has not been reported. [41] Benzoyl peroxide products are available over the counter and by prescription in a variety of topical forms, including soaps, washes, lotions, creams, and gels. Benzoyl peroxide products may be used once or twice a day. These agents may occasionally cause a true allergic contact dermatitis. More often, an irritant contact dermatitis develops, especially if used with tretinoin or when accompanied by aggressive washing methods. [41] If intensive erythema and pruritus develop, a patch test with benzoyl peroxide is indicated to rule out allergic contact dermatitis.\nSystemic treatments\nOral antibiotics\nSystemic antibiotics are a mainstay in the treatment of moderate-to-severe inflammatory acne vulgaris. [33] These agents have anti-inflammatory properties, and they are effective against C acnes (formerly P acnes). The tetracycline group of antibiotics is commonly prescribed for acne. The more lipophilic antibiotics, such as doxycycline and minocycline, are generally more effective than tetracycline. [33]\nSarecycline is a new first-in-class tetracycline-derived antibiotic indicated for adults and children aged 9 years and older with non-nodular moderate-to-severe acne vulgaris. Compared with currently available tetracyclines, it has a narrow spectrum of activity, including less activity against enteric gram-negative bacteria, and it also elicits anti-inflammatory effects. Clinical trials showed efficacy compared with placebo to be statistically significant. Onset of efficacy, observed by improvement of inflammatory lesions, was evident at the first follow-up visit (ie, 3 weeks). [42]\nGreater efficacy may also be due to less C acnes (formerly P acnes) resistance to minocycline. However, C acnes (formerly P acnes) resistance is becoming more common with all classes of antibiotics currently used to treat acne vulgaris. [43] C acnes (formerly P acnes) resistance to erythromycin has greatly reduced its usefulness in the treatment of acne. [33]\nSubantimicrobial therapy or concurrent treatment with topical benzoyl peroxide may reduce the emergence of resistant strains. [44] Comparing subantimicrobial 40-mg doxycycline, 100-mg doxycycline, and placebo, Moore et al found a comparable percentage of patients clear of acne between at the 40-mg and 100-mg doses, both significantly higher than placebo. [45] Additionally, less drug-related adverse events were found with the 40-mg subantimicrobial dosing. Enteric-coated, delayed-release formulations of doxycycline can further reduce gastrointestinal adverse effects. [46]\nOral antibiotic use can lead to vaginal candidiasis; doxycycline can be associated with photosensitivity; and minocycline has been linked to pigment deposition of the skin, mucous membranes, and teeth. [33]\nThe emergence of antibiotic-resistant bacteria, other than C acnes (formerly P acnes), is a contentious debate. An early study by Miller et al found increased skin carriage of coagulase-negative staphylococci in not only acne patients with prolonged use of antibiotics, but also in their close contacts. [47] On the contrary, a study by Fanelli et al found that Staphylococcus aureus remained sensitive to tetracycline even after prolonged use of that antibiotic for acne. [48] This has significant ramifications when considering efforts to control the spread of methicillin-resistant S aureus (MRSA), because tetracycline group antibiotics are currently one of the primary options for outpatient treatment of MRSA infection.\nOther antibiotics, including trimethoprim alone or in combination with sulfamethoxazole, and azithromycin, reportedly are helpful. [49, 50]\nHormonal therapies\nSome hormonal therapies may be effective in the treatment of acne vulgaris. Estrogen can be used to decrease sebum production. Additionally, it reduces ovarian production of androgens by suppressing gonadotrophin release. [35] Oral contraceptives also increase hepatic synthesis of sex hormone–binding globulin, resulting in an overall decrease in circulating free testosterone. Combination birth control pills have shown efficacy in the treatment of acne vulgaris. [51]\nSpironolactone may also be used in the treatment of acne vulgaris. [52] Spironolactone binds the androgen receptor and reduces androgen production. Adverse effects include dizziness, breast tenderness, and dysmenorrhea. [35] Dysmenorrhea may be lessened by coadministration with an oral contraceptive. In two 2017 retrospective studies, spironolactone has been shown to be effective in reducing inflammatory lesions in multiple areas of the body with minimal adverse effects. [53, 54] Currently, more high-powered randomized controlled trials are needed to assess the efficacy of spironolactone monotherapy in treating acne, but spironolactone should be considered in recalcitrant acne, in women who do not tolerate or have contraindications to oral contraceptives, and to prevent antibiotic resistance. [35] A 2015 large retrospective study of healthy women aged 18-45 years confirms potassium monitoring is unnecessary for these patients while taking spironolactone. [55] Pregnancy must be avoided while taking spironolactone because of the risk of feminization of the male fetus, and spironolactone is not recommended for males because of the potential for gynecomastia. [35, 53] While a black box warning regarding possible cancer risk was placed on spironolactone many years ago after rats fed high doses of the medication developed both benign and malignant tumors, several large retrospective and longitudinal studies have found no association with cancer. [56]\nIsotretinoin is a systemic retinoid that is highly effective in the treatment of severe, recalcitrant acne vulgaris. [33] Isotretinoin causes normalization of epidermal differentiation, depresses sebum excretion by 70%, is anti-inflammatory, and even reduces the presence of C acnes (formerly P acnes). [57]\nIsotretinoin therapy should be initiated at a dose of 0.5 mg/kg/d for 4 weeks and increased as tolerated until a cumulative dose of 120-150 mg/kg is achieved. [33] Coadministration with steroids at the onset of therapy may be useful in severe cases to prevent initial worsening. [33] Some patients may respond to doses lower than the standard recommendation dosages. A lower dose (0.25-0.4 mg/kg/d) may be as effective in clearing acne as the higher dose given for the same period and with greater patient satisfaction. However, the benefit of prolonged remission is not as great with such therapy as with standard doses. [58] Lower intermittent dosing schedules (1 wk/mo) are not as effective. [58]\nSome patients only require one course of oral isotretinoin for complete acne remission, while others require additional courses of isotretinoin therapy. A study found 38% of the patients had no acne during 3-year follow up, and, among the remaining patients, 17% were controlled with further topical therapy, 25% with topical and oral antibiotics, and 20% with second course of isotretinoin. [59] Relapse is more likely in younger or female patients. [59]\nIsotretinoin is a teratogen, so pregnancy must be avoided. Contraception counseling is mandatory, and two negative pregnancy test results are required prior to the initiation of therapy in women of childbearing potential. The baseline laboratory examination should also include cholesterol and triglyceride assessment, hepatic transaminase levels, and a CBC count. Pregnancy tests and a lipid panel and liver enzyme examination should be repeated monthly during treatment while dosing is changing. Once a level dose is used and the lipids, liver enzymes, and CBC count are normal, these tests may be discontinued. [35] Other adverse effects include dry skin, lips, and eyes; muscle aches; and headaches. Patients experiencing severe headaches, decreased night vision, or adverse psychiatric events should stop taking isotretinoin immediately. [35]\nAcne-associated mood changes and depression have also been reported during treatment, but a 2017 meta-analysis involving 1411 cases found no increased risk of depression with isotretinoin use. [60] Some of the studies that reported a positive causal relationship between isotretinoin and depression included a dose-response relationship with depression of up to 3 mg/kg/day of isotretinoin; however, this high of a dose is not usually prescribed for acne. [61] Other studies have described new-onset depression in both isotretinoin and antibiotic groups, suggesting depression is associated with acne, regardless of treatment. [62] Therefore, it is important to consider the risk of depression among all patients with acne.\nInflammatory bowel diseases (IBDs) have also been controversially linked to isotretinoin use. A number of case reports have linked isotretinoin with the onset of IBD, with a wide variety of severity of acne, dose of isotretinoin, and duration of treatment prior to the development of IBD. [63] Subsequent case-control and cohort studies had conflicting results, with some suggesting no association between isotretinoin and IBD and others suggesting an association between isotretinoin and ulcerative colitis but not Crohn disease [64, 65, 66, 67] Finally, a 2016 large meta-analysis, indexing more than 9 million cases to reduce effects of selection bias and confounding factors, showed isotretinoin is not associated with an increased risk of Crohn disease or ulcerative colitis. [68] A US Food and Drug Administration(FDA)–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.\nWhile using isotretinoin, the patient is considered at high risk for abnormal healing and the development of excessive granulation tissue following procedures. [69] Many dermatologists delay elective procedures, such as dermabrasion or laser resurfacing (eg, with carbon dioxide laser or erbium:YAG laser), for up to 1 year after completion of therapy.\nIntralesional steroid injections have been found to be beneficial for large inflammatory lesions. Comedone removal does not affect the course of the disease, but it does improve the patient’s appearance. [33] Additionally, some patients may benefit from superficial peels that use glycolic or salicylic acid, although more research needs to be conducted to establish best practice for these modalities.\nOf all forms of laser and light therapy, the most evidence is with photodynamic therapy (PDT) in treating acne. [33] PDT involves a photosensitizer applied to the skin, time allowed for it to be absorbed by the pilosebaceous units, and then application of a light source to activate the photosensitizer, generating reactive oxygen species to damage the glands and reduce Cutibacterium acnes (formerly Propionibacterium acnes). A 2016 Cochrane review was unable to draw firm conclusions regarding the benefit of light therapy in acne, owing to the variation in wavelength, dose, photosensitizer, comparator interventions, and treatment frequency that were studied. [70] However, despite the interstudy variation, many individual trials show PDT to be effective in reducing lesions in mild-to-severe acne, with 5-aminolevulinic acid and methyl aminolevulinate photosensitizers and red light source as promising treatment components. [71, 72]\nThere is also a growing body of evidence for laser treatment of acne, standalone or in the context of PDT. However, similar to light therapy, the power and quality of research is limited by small patient numbers, lack of a control population, and comparison to standard therapies. Nonetheless, preliminary studies have shown improvement in acne, and even potential long-lasting effects with the 1550-nm erbium-glass laser, 1064-nm Nd:YAG laser, and PDT with laser. [73]\nIn December 2014, the FDA approved Bellafill, the first dermal filler indicated for acne scarring. Bellafill is a bovine collagen dermal filler.\nIf the patient is feeling depressed while taking isotretinoin, refer him or her to a specialist for help.\nDiet therapy has been suggested. Fulton et al performed a study on chocolate, having teenage patients with acne consume 1 bar of chocolate each day. Some of the patients improved and some worsened, but the vast majority were unchanged. [74] This study helped decrease the emphasis on diet as a causal factor in acne vulgaris. However, investigators always returned to the diet question. Data suggest that the westernization of certain Native American populations and the related consumption of unhealthy \"junk\" foods (eg, potato chips, soft drinks) has had a negative impact on general and skin health, resulting in acne flares. Skim milk, compared with full-fat milk, has been found to have a positive association with acne, especially in teenagers and young adults. [75, 76] Causation was not able to be drawn from the case control studies, but the mechanism involving hormonal constituents of the skim milk has been postulated. [75] . Whey protein is a commonly used supplement that has been suggested to worsen acne and should be discontinued if flaring of the condition is associated with its use.\nInvestigators have also focused on a low-glycemic diet to avoid stress from high-carbohydrate diets and to reduce insulin levels. A study found that 12 weeks of a high-protein, low–glycemic load diet decreased the total amount of acne lesions, and this may lead to dermatologists recommending the South Beach Diet to patients with acne. [23] However, guideline groups have not found benefit in acne treatment or control with dietary restrictions. [33]\nHyperkalemia is a potential dangerous adverse effect from spironolactone; however, a 2015 large retrospective study of healthy women aged 18-45 years confirms potassium monitoring is unnecessary for these patients while taking spironolactone. [55] Plovanich et al found the rate of hyperkalemia in patients taking spironolactone is equivalent to the minimal baseline rate of hyperkalemia in this population, and, of the hyperkalemia cases, none was clinically significant.\nDawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013 May 8. 346:f2634. [Medline].\nThiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May. 60(5 Suppl):S1-50. [Medline].\nGoulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol. 1999 Aug. 141(2):297-300. [Medline].\nKellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999 Feb. 140(2):273-82. [Medline].\nKelhälä HL, Fyhrquist N, Palatsi R, et al. Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation. Exp Dermatol. 2016 Jun. 25 (6):477-8. [Medline]. [Full Text].\nSaluja SS, Walker ML, Summers EM, Tristani-Firouzi P, Smart DR. Safety of non-ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: A randomized split-face controlled trial. Lasers Surg Med. 2017 Dec. 49 (10):886-890. [Medline].\nCollier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan. 58(1):56-9. [Medline].\nJeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003 Jul. 121(1):20-7. [Medline].\nNorris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988 May. 118(5):651-9. [Medline].\nKim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1. 169(3):1535-41. [Medline].\nWebster GF. Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology. 1998. 196(1):80-1. [Medline].\nPochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin. 1988 Jul. 6(3):349-51. [Medline].\nLucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr. 1997 Jan. 130(1):30-9. [Medline].\nBaek JH, Ahn SM, Choi KM, Jung MK, Shin MK, Koh JS. Analysis of comedone, sebum and porphyrin on the face and body for comedogenicity assay. Skin Res Technol. 2016 May. 22 (2):164-9. [Medline].\nTrivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006 Sep. 126(9):2002-9. [Medline].\nSmith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol. 2006 Jun. 126(6):1226-32. [Medline].\nZouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes -- a pathogenetic link between stress and acne. Exp Dermatol. 2004. 13 Suppl 4:31-5. [Medline].\nDavis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010 Apr. 3(4):24-38. [Medline]. [Full Text].\nMomin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010 Jun. 9(6):627-36. [Medline].\nMango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception. 1996 Mar. 53(3):163-70. [Medline].\nBasler RS. Acne mechanica in athletes. Cutis. 1992 Aug. 50(2):125-8. [Medline].\nAmerican Academy of Dermatology. Skin conditions by the numbers. www.aad.org. Available at https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed: March 26, 2019.\nSmith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol. 2007 Aug. 57(2):247-56. [Medline].\nShaw JC, White LE. Persistent acne in adult women. Arch Dermatol. 2001 Sep. 137(9):1252-3. [Medline].\n[Guideline] Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013 May. 131 Suppl 3:S163-86. [Medline].\nKligman AM. Postadolescent acne in women. Cutis. 1991 Jul. 48(1):75-7. [Medline].\nBarnes LE, Levender MM, Fleischer AB Jr, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012 Apr. 30(2):293-300, ix. [Medline].\nUgge H, Udumyan R, Carlsson J, Andrén O, Montgomery S, Davidsson S, et al. Acne in late adolescence and risk of prostate cancer. Int J Cancer. 2017 Dec 4. [Medline].\nMulcahy N. Teen Acne Tied to Prostate Cancer Risk. Medscape News & Perspective. Available at https://www.medscape.com/viewarticle/890102#vp_1. December 14, 2017; Accessed: December 15, 2017.\nSutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer. 2007 Dec 15. 121 (12):2688-92. [Medline].\nHousman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol. 2014 Nov. 71 (5):847.e1-847.e10; quiz 857-8. [Medline].\nSchmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. JAMA Dermatol. 2016 Apr. 152 (4):391-8. [Medline].\n[Guideline] Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May. 74 (5):945-973.e33. [Medline].\nCunliffe WJ, Holland DB, Jeremy A. Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol. 2004 Sep-Oct. 22(5):367-74. [Medline].\nGollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul. 49(1 Suppl):S1-37. [Medline].\nThielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008. 9(6):369-81. [Medline].\nZaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg. 2008 Sep. 27(3):177-82. [Medline].\nEichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin JE, Berk DR, et al. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. J Drugs Dermatol. 2016 Aug 1. 15 (8):962-9. [Medline].\nRaoof TJ, Hooper D, Moore A, Zaiac M, Sullivan T, Kircik L, et al. Efficacy and Safety of a Novel Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: A Phase 3 Study. J Am Acad Dermatol. 2019 Jun 1. [Medline]. [Full Text].\nGold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019 Jan. 80 (1):168-177. [Medline].\nCunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. Acta Derm Venereol. 1981. 61(3):267-9. [Medline].\nMoore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol. 2018 Sep 1. 17 (9):987-996. [Medline].\nEady EA, Jones CE, Gardner KJ, Taylor JP, Cove JH, Cunliffe WJ. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993 May. 128(5):556-60. [Medline].\nToossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008 Dec. 7(12):1149-52. [Medline].\nMoore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study. J Drugs Dermatol. 2015 Jun. 14 (6):581-6. [Medline].\nValentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009 Aug 12. 2:129-40. [Medline].\nMiller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996 Nov. 38(5):829-37. [Medline].\nFanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, Acne, and Staphylococcus aureus Colonization. Arch Dermatol. 2011 Aug. 147(8):917-21. [Medline].\nBottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology. 1993. 187(3):193-6. [Medline].\nFernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000 Jan. 39(1):45-50. [Medline].\nKoulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis. 2000 Oct. 66(4):281-6. [Medline].\nShaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000 Sep. 43(3):498-502. [Medline].\nCharny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017 Jun. 3 (2):111-115. [Medline].\nGrandhi R, Alikhan A. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. Dermatology. 2017. 233 (2-3):141-144. [Medline].\nPlovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015 Sep. 151 (9):941-4. [Medline].\nTrivedi MK, Shinkai K, Murase JE. A Review of hormone-based therapies to treat adult acne vulgaris in women. Int J Womens Dermatol. 2017 Mar. 3 (1):44-52. [Medline].\nWard A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs. 1984 Jul. 28(1):6-37. [Medline].\nLee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of Conventional, Low-dose and Intermittent Oral Isotretinoin in the Treatment of Acne: A Randomized, Controlled Comparative study. Br J Dermatol. 2010 Nov 29. [Medline].\nWhite GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998 Mar. 134(3):376-8. [Medline].\nHuang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jun. 76 (6):1068-1076.e9. [Medline].\nBremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry. 2012 Jan. 73 (1):37-50. [Medline].\nSuarez B, Serrano A, Cova Y, Baptista T. Isotretinoin was not associated with depression or anxiety: A twelve-week study. World J Psychiatry. 2016 Mar 22. 6 (1):136-42. [Medline].\nCrockett SD, Gulati A, Sandler RS, Kappelman MD. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol. 2009 Oct. 104 (10):2387-93. [Medline].\nAlhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol. 2013 Apr. 133 (4):907-12. [Medline].\nRashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014 Dec. 150 (12):1322-6. [Medline].\nEtminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013 Feb. 149 (2):216-20. [Medline].\nCrockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010 Sep. 105 (9):1986-93. [Medline].\nLee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016 Feb. 28 (2):210-6. [Medline].\nBagatin E, dos Santos Guadanhim LR, Yarak S, Kamamoto CS, de Almeida FA. Dermabrasion for acne scars during treatment with oral isotretinoin. Dermatol Surg. 2010 Apr. 36(4):483-9. [Medline].\nBarbaric J, Abbott R, Posadzki P, Car M, Gunn LH, Layton AM, et al. Light therapies for acne. Cochrane Database Syst Rev. 2016 Sep 27. 9:CD007917. [Medline].\nBoen M, Brownell J, Patel P, Tsoukas MM. The Role of Photodynamic Therapy in Acne: An Evidence-Based Review. Am J Clin Dermatol. 2017 Jun. 18 (3):311-321. [Medline].\nKeyal U, Bhatta AK, Wang XL. Photodynamic therapy for the treatment of different severity of acne: A systematic review. Photodiagnosis Photodyn Ther. 2016 Jun. 14:191-9. [Medline].\nWiznia LE, Stevenson ML, Nagler AR. Laser treatments of active acne. Lasers Med Sci. 2017 Aug 4. [Medline].\nFulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA. 1969 Dec 15. 210(11):2071-4. [Medline].\nLaRosa CL, Quach KA, Koons K, Kunselman AR, Zhu J, Thiboutot DM, et al. Consumption of dairy in teenagers with and without acne. J Am Acad Dermatol. 2016 Aug. 75 (2):318-22. [Medline].\nDi Landro A, Cazzaniga S, Parazzini F, Ingordo V, Cusano F, Atzori L, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol. 2012 Dec. 67 (6):1129-35. [Medline].\n[Guideline] American Academy of Dermatology. Ten Things Physicians and Patients Should Question. Choosing Wisely. April 30, 2016. Available at http://www.choosingwisely.org/societies/american-academy-of-dermatology/. August 19, 2015;\n[Guideline] Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2015 Nov 16. [Medline]. [Full Text].\nHarding A. Canadian dermatologists issue new acne treatment guidelines. Reuters Health Information. Available at http://www.medscape.com/viewarticle/854601. November 18, 2015; Accessed: December 11, 2015.\nFDA safety alert. Over-The-Counter Topical Acne Products: Drug Safety Communication - Rare But Serious Hypersensitivity Reactions. U.S. Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402722.htm. Accessed: June 30, 2014.\nAcne, grade I; multiple open comedones.\nAcne, grade II; closed comedones.\nAcne, grade III; papulopustules.\nAcne, grade IV; multiple open comedones, closed comedones, and papulopustules, plus cysts.\nJaggi Rao, MD, FRCPC Clinical Professor of Medicine, Division of Dermatology and Cutaneous Sciences, Director of Dermatology Residency Program, University of Alberta Faculty of Medicine and Dentistry, Canada\nJaggi Rao, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, Canadian Dermatology Association, Canadian Medical Association, Canadian Medical Protective Association, Pacific Dermatologic Association, Royal College of Physicians and Surgeons of Canada\nJennifer Chen, MD Department of Family and Community Medicine, University of Toronto Faculty of Medicine, Canada\nDavid F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic\nDavid F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for MOHS Surgery, Association of Military Dermatologists, Phi Beta Kappa\nWilliam D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine\nWilliam D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology\nDisclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.\nJoshua A Zeichner, MD Assistant Professor, Director of Cosmetic and Clinical Research, Mount Sinai School of Medicine; Chief of Dermatology, Institute for Family Health at North General\nJoshua A Zeichner, MD is a member of the following medical societies: American Academy of Dermatology, National Psoriasis Foundation\nDisclosure: Received consulting fee from Valeant for consulting; Received grant/research funds from Medicis for other; Received consulting fee from Galderma for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Pharmaderm for consulting; Received consulting fee from Onset for consulting.\nencoded search term (Acne Vulgaris) and Acne Vulgaris\nFast Five Quiz: What Do You Know About Acne?\nCutibacterium (Propionibacterium) Infections\nFast Five Quiz: Test Yourself on Key Aspects of Summer Skin Conditions\nFDA OKs First Tazarotene Lotion (Arazlo) for Acne Vulgaris\nFDA Clears First Topical Form of Minocycline for Acne\nBlue-Light Therapy for Acne Vulgaris\nIdentifying Lesions on Skin of Color\nAccording to Dermatologists\nCollagen: 'Fountain of Youth' or Edible Hoax?\nEvidence Growing That Eczema Itch More Than Skin Deep\nShingrix for Herpes Zoster: A Review\nSkin, Hair and Nail Supplements\nSunscreen Photoprotection and Vitamin D Status\nJournal Article Development of a New Patient-reported Outcome Measure to Evaluate Treatments for Acne and Acne Scarring: The ACNE-Q\nDiseases & Conditions Acneiform Eruptions\n2010 /viewarticle/923600\nFast Five Quiz: Acne Practice Essentials\nDiseases & Conditions Acne Vulgaris"